Skip to main content
. 2017 Jul 22;39(8):699–709. doi: 10.1093/eurheartj/ehx353

Table 2.

Patients stratified according to late gadolinium enhancement or extracellular volume median value

LGE
ECV
<10.5 g (n = 65)  > =10.5 g (n = 66) P-value <28.4% (n = 58)  > =28.4% (n = 58) P-value
Age (years) 68.8  ± 10.4 71.7  ± 8.8 0.089 70.3  ± 10.0 70.1  ± 9.7 0.910
Gender (male/female) 28/37 45/21 0.004 34/24 31/27 0.575
BMI (kg/m2) 28.7  ± 5.5 28.2  ± 4.7 0.567 27.8  ± 5.0 29.3  ± 5.0 0.097
Comorbidities, n (%)
 HTN 44 (68%) 56 (89%) 0.006 43 (75%) 49 (84%) 0.225
 AF 6 (9%) 13 (20%) 0.089 7 (12%) 11 (19%) 0.305
 CAD 14 (22%) 29 (45%) 0.015 19 (33%) 21 (36%) 0.746
Symptom, n (%)
 Syncope 6 (9%) 4 (6%) 0.600 6 (10%) 4 (7%) 0.489
 NYHA 0.721 0.040
  I 8 (12%) 9 (14%) 8 (14%) 5 (9%)
  II 33 (51%) 28 (42%) 34 (59%) 24 (41%)
  III 17 (26%) 23 (35%) 13 (22%) 21 (36%)
  IV 2 (3%) 2 (3%) 0 (0%) 4 (7%)
 Chest pain 0.288 0.982
  0 41 (63%) 39 (59%) 35 (60%) 37 (64%)
  1 3 (5%) 7 (11%) 5 (9%) 5 (9%)
  2 15 (23%) 8 (12%) 12 (21%) 10 (18%)
  3 4 (6%) 5 (8%) 4 (7%) 5 (9%)
Valve type, bi/tri (n) 20/45 18/48 0.659 16/42 17/41 0.837
AVAi (cm2/m2) 0.41  ± 0.14 0.40  ± 0.13 0.605 0.42  ± 0.15 0.39  ± 0.11 0.384
Mean gradient (mmHg) 44.8  ± 11.9 47.8  ± 14.7 0.216 47.1  ± 14 44.8  ± 13 0.368
Mitral regurgitation (%) 7.4  ± 11.2 15.2  ± 14.3 0.012 9.1  ± 12.7 11.5  ± 12.9 0.428
EDVi (mL/m2) 63.2  ± 20.9 70.2  ± 21.9 0.045 61.0  ± 19.1 71.4  ± 24.7 0.012
ESVi (mL/m2) 19.0  ± 15.6 25.6  ± 20.7 0.041 16.9  ± 12.0 27.7  ±   ± 23.3 0.002
LVMi (g/m2) 83.9  ± 27.5 90.7  ± 20.7 0.035 83.7  ± 24.4 91.8  ± 25.6 0.085
LVEF (%) 72.4  ± 13.2 67.1  ± 15.4 0.032 73.9  ± 11.4 65.6  ± 17.0 0.003
MAPSE (mm) 10.7  ± 3.5 9.8  ± 3.6 0.123 11.0  ± 3.2 9.53  ± 3.7 0.031
LAAi (cm2/m2) 12.7  ± 3.3 14.5  ± 4.2 0.006 12.8  ± 3.3 14.4  ± 4.6 0.081
E/A 0.91  ± 0.42 1.08  ± 0.58 0.084 0.87  ± 0.38 1.10  ± 0.59 0.022
DT (ms) 245  ± 69 227  ± 82 0.206 236  ± 72 237  ± 81 0.940
E/e' 13.57  ± 6.28 13.94  ± 6.11 0.771 12.46  ± 6.27 14.94  ± 5.96 0.018
6MWT (m) 468  ± 190 412  ± 187 0.143 488  ± 145 393  ± 210 0.006
ECV (%) 27.5  ± 2.6 29.5  ± 2.8 <0.001 26.0  ± 1.7 30.7  ± 1.8 <0.001
LGE (g) 5.84  ± 2.5 22.8  ± 9.9 <0.001 11.5  ± 9.1 15.4  ± 12.2 0.090
CVF (%) 7.3  ± 4.7 15.7  ± 9.8 <0.001 10.4  ± 7.5 10.9  ± 8.5 0.707
NT-proBNP (pg/mL) 96  ± 139 277  ± 341 <0.001 99  ± 154 262  ± 335 <0.001
hs-TnT (ng/L) 15  ± 10 21  ± 20 0.001 15  ± 13 21  ± 18 0.018

Boldface values indicate statistically significant P-values. Values are given as mean  ± SD or n (and percentage).

LGE, late gadolinium enhancement; ECV, extracellular volume; BMI, body mass index; HTN, hypertension; AF, atrial fibrillation; CAD, coronary arterial disease; EDVi, end-diastolic volume index; ESVi, end-systolic volume index; LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction; MAPSE, mitral annular plane systolic excursion; LAAi, left atrial area index; E, peak early velocity of the transmitral flow; A, peak late velocity of the transmitral flow; DT, deceleration time; E´, peak early diastolic velocity of the mitral annulus displacement; 6MWT, 6-minute-walk test; bi, bicuspid; tri, tricuspid; AVAi, aortic valve area index; CVF, collagen volume fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T; SD, standard deviation; NYHA, New York Heart Association.